| Identification | Back Directory | [Name]
Elomotecan | [CAS]
220998-10-7 | [Synonyms]
Elomotecan
(R)-EloMotecan
(5R)-9-Chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione,9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-,(5R)- | [Molecular Formula]
C29H32ClN3O4 | [MOL File]
220998-10-7.mol | [Molecular Weight]
522.04 |
| Hazard Information | Back Directory | [Uses]
Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II[1]. | [IC 50]
Topoisomerase I; Topoisomerase II | [References]
[1] Trocóniz IF, et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(2):239-250. DOI:10.1007/s00280-012-1906-y |
|
|